These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1771827)

  • 1. [Pseudomonas aeruginosa preparations for active immunization].
    Nazarchuk LV
    Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
    [No Abstract]   [Full Text] [Related]  

  • 2. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
    Cryz SJ; Sadoff JC; Que JU
    Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness of immunization with single and multi-component vaccines prepared from a common antigen (OEP), protease and elastase toxoids of Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink due to P. aeruginosa.
    Homma JY; Abe C; Tanamoto K; Hirao Y; Morihara K; Tsuzuki H; Yanagawa R; Honda E; Aoi Y; Fujimoto Y; Goryo M; Imazeki N; Noda H; Goda A; Takeuchi S; Ishihara T
    Jpn J Exp Med; 1978 Apr; 48(2):111-33. PubMed ID: 101698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
    Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
    Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of elastase, protease and common antigen (OEP) from Pseudomonas aeruginosa on protection against burns in mice.
    Kawaharajo K; Homma JY
    Jpn J Exp Med; 1977 Dec; 47(6):495-500. PubMed ID: 416253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
    Okada K; Kawaharajo K; Kasai T; Homma JY
    Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic considerations for the development of conjugate vaccines.
    Garner CV; Pier GB
    Contrib Microbiol Immunol; 1989; 10():11-7. PubMed ID: 2510971
    [No Abstract]   [Full Text] [Related]  

  • 13. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections.
    Sourek J
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of experimental burn wound sepsis by postburn immunization with polyvalent Pseudomonas antigen.
    Nance FC; Hines JL; Fulton RE; Bornside GH
    Surgery; 1970 Jul; 68(1):248-53. PubMed ID: 10483476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinations against Pseudomonas aeruginosa: active and passive alternatives.
    Bellanti JA; Zeligs BJ; Kulczycki LL
    Pediatr Pulmonol Suppl; 1997; 16():269-70. PubMed ID: 9443307
    [No Abstract]   [Full Text] [Related]  

  • 16. [Cell-free Pseudomonas vaccine. IV. Laboratory trials of the effectiveness of experimental Pseudomonas vaccines].
    Stanislavskiĭ ES; Joó I; Bulk VF; Zhvanetskaia MI; Mashilova GM
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Oct; (10):25-9. PubMed ID: 6817559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of immunological preparations and their use for preventing and treating pyocyanic infection in burn patients].
    Kolker II; Stanislavskiĭ ES; Grishina IA; Panova IuM; Krokhina MA
    Probl Gematol Pereliv Krovi; 1981 Jan; 26(1):29-33. PubMed ID: 6784114
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice.
    Smith RL; Wysocki JA; Bruun JN; De Courcy SJ; Blakemore WS; Mudd S
    J Reticuloendothel Soc; 1974 Jan; 15(1):22-30. PubMed ID: 4204145
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experimental infection of immunized mice homologous and heterologous serotypes with Pseudomonas aeruginosa].
    Vidal G; Mynard MC
    Ann Inst Pasteur (Paris); 1972 Jun; 122(6):1129-35. PubMed ID: 4627762
    [No Abstract]   [Full Text] [Related]  

  • 20. A multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase, exotoxin A and a common protective antigen (OEP). Application in patients with diffuse panbronchiolitis.
    Homma JY; Tanimoto H
    Antibiot Chemother (1971); 1987; 39():215-21. PubMed ID: 3118783
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.